$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

하지불안증후군/윌리스-엑봄병의 병태생리
The Pathophysiology of Restless Legs Syndrome/Willis-Ekbom Disease 원문보기

수면·정신생리 = Sleep medicine and psychophysiology, v.28 no.2, 2021년, pp.43 - 52  

신재공 (용인정신병원, 용인정신의학연구소)

Abstract AI-Helper 아이콘AI-Helper

Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a sleep disorder characterized by sensorimotor symptoms such as unpleasant sensations before sleep, akathisia, and periodic limb movements during sleep. It is also closely related to hyperarousal and is often accompanied by insomnia. Although ...

주제어

참고문헌 (100)

  1. Akcimen F, Sarayloo F, Liao C, Ross JP, Oliveira RB, Dion PA, et al. Transcriptome-wide association study for restless legs syndrome identifies new susceptibility genes. Commun Biol 2020;3:373. 

  2. Allen, Montplaisir J, Walters AS, Ferini-Strambi L HB. Restless Legs Syndrome and Periodic Limb Movements During Sleep. In: Kryger M, Roth T. Principles and Practice of Sleep Medicine (Sixth Edition). Philadelpha: Elsevier, 2017:923-934. 

  3. Allen RP. Restless leg syndrome/willis-ekbom disease pathophysiology. Sleep Med Clin 2015;10:207-214. 

  4. Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol 2013;88:261-264. 

  5. Allen RP, Barker PB, Horska A, Earley CJ. Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology 2013;80:2028-2034. 

  6. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009;10:123-128. 

  7. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007;22 Suppl 18:S440-S448. 

  8. Allen RP, Earley CJ, Jones BC, Unger EL. Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome. Sleep Med 2020;71:141-148. 

  9. Allen RP, La Buda MC, Becker P, Earley CJ. Family history study of the restless legs syndrome. Sleep Med 2002;3 Suppl:S3-7. 

  10. Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 2018;41:27-44. 

  11. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med 2014;15:860-873. 

  12. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-1292. 

  13. Ashraf A, Clark M, So PW. The aging of iron man. Front Aging Neurosci 2018;10:65. 

  14. Berger K, von Eckardstein A, Trenkwalder C, Rothdach A, Junker R, Weiland SK. Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. J Neurol 2002;249:1195-1199. 

  15. Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness. Physiol Rev 2012;92:1087-1187. 

  16. Chawla S, Gulyani S, Allen RP, Earley CJ, Li X, Van Zijl P, et al. Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. Sleep 2019;8:42:zsz079. 

  17. Chenini S, Delaby C, Rassu AL, Barateau L, Vialaret J, Hirtz C, et al. Hepcidin and ferritin levels in restless legs syndrome: a case-control study. Scientific Reports 2020;10:1-10. 

  18. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M, et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 2006;26:2080-2087. 

  19. Ciruela F, Ferre S, Casado V, Cortes A, Cunha RA, Lluis C, et al. Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cell Mol Life Sci 2006;63:2427-2431. 

  20. Clardy SL, Wang X, Boyer PJ, Earley CJ, Allen RP, Connor JR. Is ferroportin-hepcidin signaling altered in restless legs syndrome? J Neurol Sci 2006;247:173-179. 

  21. Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006;67:125-130. 

  22. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61:304-309. 

  23. Connor JR, Patton SM, Oexle K, Allen RP. Iron and restless legs syndrome: treatment, genetics and pathophysiology. Sleep Med 2017;31:61-70. 

  24. Connor JR, Ponnuru P, Wang XS, Patton SM, Allen RP, Earley CJ. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011;134:959-968. 

  25. Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009;132:2403-2412. 

  26. Dauvilliers Y, Chenini S, Vialaret J, Delaby C, Guiraud L, Gabelle A, et al. Association between serum hepcidin level and restless legs syndrome. Mov Disord 2018;33:618-627. 

  27. Dean T Jr, Allen RP, O'Donnell CP, Earley CJ. The effects of dietary iron deprivation on murine circadian sleep architecture. Sleep Med 2006;7:634-640. 

  28. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82. 

  29. Drgonova J, Walther D, Wang KJ, Hartstein GL, Lochte B, Troncoso J, et al. Mouse Model for Protein Tyrosine Phosphatase D (PTPRD) associations with restless leg syndrome or willis-ekbom disease and addiction: reduced expression alters locomotion, sleep behaviors and cocaine-conditioned place preference. Mol Med 2015;21:717-725. 

  30. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annual Review of Neuroscience 2001;24:31-55. 

  31. Earley CJ, Allen RP, Connor JR, Ferrucci L, Troncoso J. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med 2009;10:1155-1157. 

  32. Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, et al. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Med 2014;15:1288-1301. 

  33. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54:1698-1700. 

  34. Earley CJ, Hyland K, Allen RP. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006;7:263-268. 

  35. Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas R, Brasic J, et al. 0The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep 2011;34:341-347. 

  36. Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas RE, Brasic JR, et al. Increased synaptic dopamine in the putamen in restless legs syndrome. Sleep 2013;36:51-57. 

  37. Earley CJ, Ponnuru P, Wang X, Patton SM, Conner JR, Beard JL, et al. Altered iron metabolism in lymphocytes from subjects with restless legs syndrome. Sleep 2008;31:847-852. 

  38. Earley CJ, Uhl GR, Clemens S, Ferre S. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Med 2017;31:71-77. 

  39. El Gewely M, Welman M, Xiong L, Yin S, Catoire H, Rouleau G, et al. Reassessing GWAS findings for the shared genetic basis of insomnia and restless legs syndrome. Sleep 2018;41:zsy164. 

  40. Ferre S. Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. Journal of Alzheimer's Disease 2010;20:S35-S49. 

  41. Ferre S, Bonaventura J, Zhu W, Hatcher-Solis C, Taura J, Quiroz C, et al. Essential control of the function of the striatopallidal neuron by pre-coupled complexes of adenosine A(2A)-dopamine D(2) receptor heterotetramers and adenylyl cyclase. Front Pharmacol 2018;9:243. 

  42. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20:482-487. 

  43. Ferre S, Garcia-Borreguero D, Allen RP, Earley CJ. New Insights into the neurobiology of restless legs syndrome. Neuroscientist 2019;25:113-125. 

  44. Ferre S, Quiroz C, Guitart X, Rea W, Seyedian A, Moreno E, et al. Pivotal role of adenosine neurotransmission in restless legs syndrome. Front Neurosci 2017;11:722. 

  45. Garcia-Borreguero D, Cano I, Granizo JJ. Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel. Sleep Med 2017;34:105-108. 

  46. Garcia-Borreguero D, Garcia-Malo C, Granizo JJ, Ferre S. A randomized, placebo-controlled crossover study with dipyridamole for restless legs syndrome. Mov Disord 2021;36:2387-2392. 

  47. Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo JJ, Ferre S. Treatment of restless legs syndrome/Willis- Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Med 2018;45:94-97. 

  48. Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep 2014;37:635-643. 

  49. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci U S A 2000;97:8606-8611. 

  50. Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord 2008;23:1184-1187. 

  51. Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord 2007;22:187-192. 

  52. Hammerschlag AR, Stringer S, de Leeuw CA, Sniekers S, Taskesen E, Watanabe K, et al. Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits. Nat Genet 2017;49:1584-1592. 

  53. Heide AC, Winkler T, Helms HJ, Nitsche MA, Trenkwalder C, Paulus W, et al. Effects of transcutaneous spinal direct current stimulation in idiopathic restless legs patients. Brain Stimul 2014;7:636-642. 

  54. Hogl B, Stefani A. Restless legs syndrome and periodic leg movements in patients with movement disorders: specific considerations. Mov Disord 2017;32:669-681. 

  55. Inoue Y, Hirata K, Kuroda K, Fujita M, Shimizu T, Emura N, et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: a polysomnographic randomized, double-blind, placebo-controlled study. Sleep Med 2010;11:11-16. 

  56. Inturrisi CE. Pharmacology of methadone and its isomers. Minerva Anestesiol 2005;71:435-437. 

  57. Jellen LC, Unger EL, Lu L, Williams RW, Rousseau S, Wang X, et al. Systems genetic analysis of the effects of iron deficiency in mouse brain. Neurogenetics 2012;13:147-157. 

  58. Jung KY, Koo YS, Kim BJ, Ko D, Lee GT, Kim KH, et al. Electrophysiologic disturbances during daytime in patients with restless legs syndrome: further evidence of cognitive dysfunction? Sleep Med 2011;12:416-421. 

  59. Kang SG, Lee HJ, Jung SW, Cho SN, Han C, Kim YK, et al. Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1078-1083. 

  60. Kang SG, Lee HJ, Kim L. Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. J Psychopharmacol 2009;23:597-601. 

  61. Kang SG. Updates on the treatment of restless leg syndrome. Sleep Med Psychophysiol 2018;25:5-8. 

  62. Kang SG. Updates on the diagnosis and treatment of restless legs syndrome. J Korean Neuropsychiatr Assoc 2020;59:13-19. 

  63. Kapur N, Friedman R. Oral ketamine: a promising treatment for restless legs syndrome. Anesth Analg 2002;94:1558-1559. 

  64. Kim KW, Yoon IY, Chung S, Shin YK, Lee SB, Choi EA, et al. Prevalence, comorbidities and risk factors of restless legs syndrome in the Korean elderly population-results from the Korean Longitudinal Study on Health and Aging. J Sleep Res 2010;19:87-92. 

  65. Lai YY, Cheng YH, Hsieh KC, Nguyen D, Chew KT, Ramanathan L, et al. Motor hyperactivity of the iron-deficient rat-an animal model of restless legs syndrome. Mov Disord 2017;32:1687-1693. 

  66. Lanza G, Cantone M, Lanuzza B, Pennisi M, Bella R, Pennisi G, et al. Distinctive patterns of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome, restless legs syndrome, insomnia, and sleep deprivation. Sleep Med Rev 2015;19:39-50. 

  67. Lyu S, Xing H, DeAndrade MP, Liu Y, Perez PD, Yokoi F, et al. The role of BTBD9 in striatum and restless legs syndrome. eNeuro 2019;6:ENEURD.0277-19.2019. 

  68. Magalhaes SC, Kaelin-Lang A, Sterr A, do Prado GF, Eckeli AL, Conforto AB. Transcranial magnetic stimulation for evaluation of motor cortical excitability in restless legs syndrome/Willis-Ekbom disease. Sleep Med 2015;16:1265-1273. 

  69. McCarthy RC, Kosman DJ. Iron transport across the blood-brain barrier: development, neurovascular regulation and cerebral amyloid angiopathy. Cell Mol Life Sci 2015;72:709-727. 

  70. McGahan MC, Harned J, Mukunnemkeril M, Goralska M, Fleisher L, Ferrell JB. Iron alters glutamate secretion by regulating cytosolic aconitase activity. Am J Physiol Cell Physiol 2005;288:C1117-C1124. 

  71. Michaud M, Chabli A, Lavigne G, Montplaisir J. Arm restlessness in patients with restless legs syndrome. Mov Disord 2000;15:289-293. 

  72. Navarro G, Cordomi A, Casado-Anguera V, Moreno E, Cai NS, Cortes A, et al. Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase. Nat Commun 2018;9:1242. 

  73. Nnah IC, Wessling-Resnick M. Brain iron homeostasis: a focus on microglial iron. Pharmaceuticals (Basel) 2018;11:129. 

  74. Nordlander NB. Therapy in restless legs. Acta Med Scand 1953;145:453-457. 

  75. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994;23:200-203. 

  76. Oertel WH, Benes H, Garcia-Borreguero D, Hogl B, Poewe W, Montagna P, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-856. 

  77. Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000;55:1404-1406. 

  78. Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C. Update of the pathophysiology of the restless-legs-syndrome. Mov Disord 2007;22 Suppl 18:S431-S439. 

  79. Peng W, Wu Z, Song K, Zhang S, Li Y, Xu M. Regulation of sleep homeostasis mediator adenosine by basal forebrain glutamatergic neurons. Science 2020;369:eabb0556. 

  80. Pinninti NR, Mago R, Townsend J, Doghramji K. Periodic restless legs syndrome associated with quetiapine use: a case report. J Clin Psychopharmacol 2005;25:617-618. 

  81. Qu S, Le W, Zhang X, Xie W, Zhang A, Ondo WG. Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol 2007;66:383-388. 

  82. Quiroz C, Gulyani S, Ruiqian W, Bonaventura J, Cutler R, Pearson V, et al. Adenosine receptors as markers of brain iron deficiency: implications for restless legs syndrome. Neuropharmacology 2016;111:160-168. 

  83. Salminen AV, Lam DD, Winkelmann J. Role of MEIS1 in restless legs syndrome: From GWAS to functional studies in mice. Adv Pharmacol 2019;84:175-184. 

  84. Sarayloo F, Dion PA, Rouleau GA. MEIS1 and restless legs syndrome: a comprehensive review. Front Neurol 2019;10:935. 

  85. Schmidauer C, Sojer M, Seppi K, Stockner H, Hogl B, Biedermann B, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 2005;58:630-634. 

  86. Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Putz B, et al. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol 2017;16:898-907. 

  87. Shukla A, Agarwal KN, Shukla GS. Latent iron deficiency alters gamma-aminobutyric acid and glutamate metabolism in rat brain. Experientia 1989;45:343-345. 

  88. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011;12:440-444. 

  89. Simpson IA, Ponnuru P, Klinger ME, Myers RL, Devraj K, Coe CL, et al. A novel model for brain iron uptake: introducing the concept of regulation. J Cereb Blood Flow Metab 2015;35:48-57. 

  90. Spieler D, Kaffe M, Knauf F, Bessa J, Tena JJ, Giesert F, et al. Restless legs syndrome-associated intronic common variant in Meis1 alters enhancer function in the developing telencephalon. Genome Res 2014;24:592-603. 

  91. Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357:639-647. 

  92. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 1998;21:371-377. 

  93. Tilch E, Schormair B, Zhao C, Salminen AV, Antic Nikolic A, Holzknecht E, et al. Identification of restless legs syndrome genes by mutational load analysis. Ann Neurol 2020;87:184-193. 

  94. Uhl GR, Martinez MJ. PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes. Ann N Y Acad Sci 2019;1451:112-129. 

  95. Unger EL, Wiesinger JA, Hao L, Beard JL. Dopamine D2 receptor expression is altered by changes in cellular iron levels in PC12 cells and rat brain tissue. J Nutr 2008;138:2487-2494. 

  96. Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry 2002;35:109-111. 

  97. Winkelmann J, Muller-Myhsok B, Wittchen HU, Hock B, Prager M, Pfister H, et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 2002;52:297-302. 

  98. Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39:1000-1006. 

  99. Yepes G, Guitart X, Rea W, Newman AH, Allen RP, Earley CJ, et al. Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol 2017;82:951-960. 

  100. Zhu XY, Wu TT, Wang HM, Li X, Ni LY, Chen TJ, et al. Correlates of nonanemic iron deficiency in restless legs syndrome. Front Neurol 2020;11:298. 

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로